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Purpose: To review the current literature on reported pulmonary, liver, and nerve adverse reactions (ARs)
of long-term Nitrofurantoin (NF) suppression in older patients treated for urinary tract infections (UTIs).
Materials and methods: An extensive literature search was performed on PubMed for the search terms
“Nitrofurantoin,” and “Nitrofurantoin and lung, pulmonary, liver, nerve or ARs”. Relevant cited papers
were also analyzed. Articles not in English, or related to children, or pregnant women were excluded.
Results: In 43 articles and other texts meeting the inclusion criteria from 1968 to 2014, rates of long-term
NF-related pulmonary ARs compared to total NF prescriptions differed worldwide, but remained
extremely small at 0.001% (USA) and 0.001% for pulmonary and hepatic ARs (France). Among all NF ARs,
rates of pulmonary ARs differed across the literature from 2% (UK), 3% (Holland), 5% (Sweden), to 7%
(Australia). Nerve ARs were reported as .0007% and liver ARs as .0003% of total prescriptions
Conclusions: Pulmonary, nerve, or liver ARs resulting from long-term NF prophylaxis in older patients
treated for UTIs are potentially serious but extremely rare, and should not deter from the cautious use of
NF in this population.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The management of recurrent urinary tract infections inwomen
tends to be challenging and can be inﬂuenced by age, renal func-
tion, the mode of recurrencednamely persistence (same bacteria)
or reinfection (different bacteria), antibiotic allergies, and strain
resistance to some antibiotics. Antibiotic resistance is a growing
concern, especially for certain classes of antibiotics such as
ﬂuoroquinolones.
Nitrofurantoin (NF) has been the focus of much attention lately,
in part due to the recommendations for its use outlined in the
Beers criteria. In 2003, the ﬁrst set of Beers criteria alerted the
public to the dangers of NF in older adults because of the “potential
for renal impairment” with a high level of severity rating.1 In 2012,
the Beers criteria update expert panel included NF on a list of drugs
potentially inappropriate to use in older adults. This time the focus
was on “potential for pulmonary toxicity,” with a quality of evi-
dence rated as moderate, and a strong strength of recommenda-
tion.2 The 2012 Beers document emphasized three additional
points: (1) avoid in patients with renal impairment (creatininel Center, 5323 Harry Hines
n.edu (P.E. Zimmern).
ociation. Published by Elsevier Ta
et al., Risks of long-term use
10.1016/j.urols.2016.07.004clearance< 60mL/min); (2) safer alternatives are available; and (3)
avoid for long-term suppression.2
For practitioners, these 2012 recommendations prompted
additional justiﬁcation to reassure concerned patients already on
NF suppression. Health insurance providers also circulated noti-
ﬁcations to physicians prescribing NF to encourage them to
reconsider their decision and change to other therapies. Subse-
quently, the Beers 2015 recommendations were issued,3 followed
very recently by a special American Urological Association white
paper on this matter to revisit the intended purpose of the Beers
criteria.4
In this context, our goal was not to reconsider the well-
established recommendations to avoid NF in older adults with
renal impairment,3 but instead to focus on the available literature
data regarding NF adverse reactions (ARs), with a special emphasis
on pulmonary, liver, and nerve toxicity in order to better commu-
nicate these risks to older women and to assist in their regular
monitoring.2. Materials and methods
An extensive literature search was performed on PubMed for
the search terms “Nitrofurantoin,” and “Nitrofurantoin and lung,
pulmonary, liver, or nerves, or ARs.” Relevant cited reviews wereiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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Table 1
Percent of reported adverse reactions across the UK, Sweden, and Holland (total
adverse reports).
Reaction UK (155) Sweden (921) Holland (unknown)
Pulmonary reaction (%) 2 5.30 3.40
Liver damage (%) 3.90 Not available 9.10
Peripheral neuropathy (%) 14.10 2.20 9.10
Note. From “Adverse reactions to nitrofurantoin in the United Kingdom, Sweden,
and Holland,” by Penn and Grifﬁn, 1982, British Medical Journal (Clinical Research
Edition), 284, p. 1440e2. Copyright 1982, BMJ Publishing Group Ltd. Adapted with
permission.
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pregnant women were excluded. Four datasets were queried:
ARs versus prescriptions of NF, ARs alone, retrospective and
prospective studies, and tallying of case study reports in older
women. As a general comment, most datasets did not provide a
separate analysis of sex involvement, and thus, although not
always clearly established in reports, the majority of data
reviewed were for women. To determine the impact of age on
pulmonary ARs, a case study subanalysis was performed in
affected women using age 65 years as a traditional cut-off for
older adults.
3. Results
The following results were extracted from 43 articles and other
texts meeting our inclusion criteria from 1968 to 2014.
3.1. Lung toxicity and avoidance of NF for long-term suppression
This result section includes data primarily on lung toxicity as it is
the most commonly involved organ. The data are presented in four
sections including: ARs, retrospective and prospective series, and
case series (Appendix 1).
3.1.1. Spectrum of pulmonary adverse reactions
Pulmonary ARs are typically divided into acute and chronic re-
actions. The acute reactions are more common and the develop-
ment of one does not appear to increase one’s risk for the other
reaction.5,6 Acute pulmonary reactions appear within days of
starting the medication.7 Patients typically report respiratory and
constitutional symptoms. Rash and eosinophilia are also common.
If the drug is stopped complete resolution is the norm; however, if
not, the reactions can become severe and progress to acute respi-
ratory distress syndrome.8 Rechallenge virtually always causes a
relapse and is not recommended.
In contrast, the chronic ARs appear months to years after drug
initiation. Persistent cough and dyspnea are the primary symp-
toms.9 A large variety of interstitial lung disease patterns have been
reported including nonspeciﬁc interstitial pneumonia, desquama-
tive interstitial pneumonia, organizing pneumonia, and eosino-
philic pneumonia.10 Drug cessation is necessary for all and
corticosteroids may be of value for severe disease or disease that
progresses despite removal of the NF. Residual disease is common
despite the above measures.
3.1.2. AR reporting compared to total NF prescriptions
Two large scale studies compared the number of reported
chronic ARs of NF to the total number of prescriptions of NF. The
ﬁrst large dataset (1953e1984) was reported by D'Arcy11 based on
adverse reports to the drug manufacturer, Norwich Eaton Phar-
maceuticals, Norwich, New York, USA, in which the rates of re-
ported ARs in a study encompassing 121,430,000 courses of
treatment were tallied.10 Pulmonary reactions were reported in
0.0002% courses of treatment, liver reactions in 0.0003% of courses,
neuropathy in 0.0007% of courses, and blood dyscrasias in 0.0004%
of courses, totaling 0.001% in chronic, severe complications.11
Notably, of all the chronic side effects, pulmonary reactions were
the least frequent, despite being the reason stated in the Beers 2012
criteria for warning against NF. Another study analyzing NF pre-
scriptions in France in 2010 compiled 261,000 prescriptions of NF,
with an estimated 1500e2500 prescriptions for treatment> 4
months.12 They estimated that chronic pulmonary or hepatic re-
actions occur in one out of every 517e862 prescriptions, or 2.9
cases/y. Meanwhile, the French Committee on Drug Monitoring
reported “severe ARs,” mainly pulmonary or hepatic for NF, with aPlease cite this article in press as: Rego LL, et al., Risks of long-term use
Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.07.004frequency of 1/20,551 NF prescriptions (0.0049%).13 This frequency
increased with treatment duration: from 1 case/24,800 for short-
term prescriptions (1 month) to 1 case/7666 for long-term pre-
scriptions (>1month). These two studies indicated that reactions to
chronic NF remained very low when compared with the amount of
prescriptions of NF.
3.1.3. AR reporting
In 1982, Penn and Grifﬁn14 compared ARs between the UK (re-
ported from the Committee on Safety of Medicines), Sweden (from
Holmberg et al5), and Holland (from the Netherlands Drug Regis-
tration Authority), noting that AR reporting varied between coun-
tries as seen in Table 1. From those data, pulmonary chronic effects
of NF ranged from 2.0% to 5.3% of adverse reports. Furthermore,
even within a country, AR reporting varied between years. For
instance, from 1964 to 1980 in the UK, AR reporting declined from
1.77% to 0.11%, but increased from 1.5% in 1965e1969 to 7.9% in
1970e1974 in Sweden. In this same Swedish study from 1966 to
1976, Holmberg et al5 analyzed 921 patients with ARs, 42 of which
were on therapy for >1 year. Of those 42 patients (mean age 68
years), 23 experienced a pulmonary AR to NF. They also noted that
risk of ARs increased with age, and that women were more at risk
compared with men.
Two other studies focused solely on pulmonary ARs. The ﬁrst
study was performed by Holmberg and Boman6 from 1966 to 1976
in Sweden, in which reports to the Swedish Adverse Drug Reaction
Committee were analyzed. Out of 447 pulmonary AR reports, 49
were due to chronic NF intake, 41 of whomwere on therapy for 10
months to >65 months. Approximately three quarters of the pa-
tients required hospitalization because of an adverse pulmonary
reaction. The median age of the women on long-term therapy was
58 years, suggesting that younger women are equally susceptible to
the chronic side effects of NF as older women are.
The second study from Australia focused on adverse outcome
reporting without comparison to the amount of prescriptions. By
2004, the Australian Adverse Drug Reactions Advisory Committee
received a total of 576 adverse reports.15 Of these 142 were pul-
monary ARs, 40 of which were chronic NF-induced pulmonary AR
reports. Older women (median> 70 years) were the predominantly
affected demographic group.15 These authors and others have
postulated this may reﬂect usage of NF.15,16 Time of onset of the AR
ranged from 8 months to 16 years. Of the 40 patients with chronic
pulmonary toxicity, 12 patients recovered and two patients died.
The remainder had persistent lung damage. This study illustrated
the unpredictable onset and rarity of pulmonary damage.
3.1.4. Retrospective studies
Two large retrospective studies focused on pulmonary ARs. In
the ﬁrst retrospective study from 1989, Jick et al17 identiﬁed 742
long-time users and 16,101 patients with ﬁrst courses of treatment
of NF, and compared their hospitalization rates. In the group of
long-time users, only one man aged 65 years was hospitalized for
dyspnea (one women aged 89 years was hospitalized for possibleof nitrofurantoin for urinary tract prophylaxis in the older patient,
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three times (women aged 46 years, 49 years, and 75 years). This
rate of 0.27% of patients on long-term NF therapy suffering from a
pulmonary complication is extremely low. Although women are
noted throughout literature to be more susceptible to NF compli-
cations, only one woman from this study had a long-term
complication. This is remarkable given that the majority of NF
prescriptions were for women. A second retrospective study from
1997 to 2002 by the Mayo Clinic identiﬁed 18 patients with chronic
pulmonary ARs (17 women, six previous smokers) aged 47e90
years (median 72) who used NF prophylactically.18 These patients
were receiving a median dosage of 100 mg NF, and their median
onset of symptoms was 23 months, with a median of 4 months of
symptoms before diagnosis. One patient died of pneumonia com-
plications 5 months later, and one patient did not improve even
after 5-years post-NF discontinuation. The remainder improved but
half required corticosteroid therapy. Residual abnormalities per-
sisted in 14 patients and only three had complete resolution. This is
a signiﬁcant rate of morbidity and mortality within a group already
known to have NF-induced pulmonary problems, but appears very
small when compared with all the patients placed on NF prophy-
laxis. Interestingly, resolution of pulmonary ARs were found to
correlate neither with length of NF usage nor with duration of
pulmonary symptoms.
3.1.5. Prospective studies
Finally, in one unique prospective study from 1975 to 1992,
Brumﬁtt and Hamilton-Miller19 charted the rates of NF ARs in 219
female patients aged 9e89 years who had planned to be on 1 year
of NF therapy at various dosages (average of 9.9 months). Although
46% of patients reported a reaction with NF at an average of 9.9
months, only one patient reported a serious complication (pe-
ripheral neuropathy), and older patients (>65 years) were as likely
to have an AR as younger patients.
3.1.6. AR case studies related to pulmonary damage
The case study literature yielded 17 case reports from 1968 to
2014 that detailed pulmonary ARs related to chronic use of NF in
older women (N¼ 25). Patient data from these reports are provided
in Appendix 1. The age results of this compilation are detailed in
Figure 1. Treatment duration ranged from 9 months to 7 years,Figure 1. Compilation of published case studies pulmonary adverse reactions (ARs) related to
years.
Please cite this article in press as: Rego LL, et al., Risks of long-term use
Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.07.004cessation of NF after symptom onset ranged from 2 weeks to >4
years, and dosage also varied from 50 mg to 300 mg. Once NF was
discontinued and corrective treatment implemented, this review of
case studies indicated that these pulmonary ARs tended to be at
least partially reversible. One patient died possibly as a result of
isoniazid, while another had a right bundle branch block, with a
total of three deaths in this cohort.20,21
3.2. Liver toxicity
Hepatic damage due to NF varies widely, from granulomatous
lesions, cirrhosis, liver necrosis, to chronic active hepatitis.22
Overall incidence for hepatic damage attributed to both long- and
short-term NF has been reported to be 0.02e0.035%, and may be
due to immunoallergic idiosyncrasy.22 The diagnosis of NF-induced
hepatic reactions is a diagnosis of exclusion, which is substantiated
upon resolution of symptoms once NF has been discontinued.22 The
only way to conﬁrm NF related hepatic reactions is by rechallenge,
which is contraindicated given its potential for adverse outcomes.23
To add to the complexity of reactions to chronic NF use, liver and
pulmonary reactions may present together.24 Thus, if a patient
presents with multiple systemic symptoms, NF toxicity should still
be considered.
3.2.1. AR reporting
One retrospective study by Stricker et al25 from the Netherlands
analyzed 52 reports of NF-induced hepatic ARs to the Netherlands
Center for Monitoring Adverse Reactions from 1963 to 1987. Thir-
teen (12 women) reports were due to “chronic” effects. Thirty-eight
reports were likely due to NF, of which 13 were due to chronic ef-
fects, and 85% were for patients aged> 65 years. Also, the incidence
for adverse hepatic reactions (chronic and acute) for women
aged> 64 years was 47%, with 18.4% of prescriptions going to that
same age group. This study does indicate that older women are
more likely to suffer from an adverse liver reaction when exposed
to NF for a long time.
3.2.2. Case reports
Individual case reports of hepatic effects due to chronic NF were
not compiled due to the comprehensive case study analysis recently
published by Sakaan et al.23 The dataset from this paper waslong-term use of nitrofurantoin (N¼ 17, representing 26 patients) in women aged> 65
of nitrofurantoin for urinary tract prophylaxis in the older patient,
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NF and analyzed. Seventeen out of 33 patients (51.5%) were
aged< 65 years when they had a chronic liver reaction to NF. From
these data, older and younger women appeared to be equally at risk
for liver toxicity with chronic NF intake. Most patients’ symptoms
(jaundice, hepatomegaly, malaise) resolved after discontinuing NF,
and in some cases, with the addition of cortisol treatment. However
onepatient (aged 33years) needed a liver transplant and sevendied,
of whom twowere children and the otherswere 47e59 years of age.
3.3. Nerve toxicity
Peripheral neuropathy is one of the chronic adverse reactions of
long-term NF use. No retrospective studies focusing on nerve
adverse reactions to chronic NF therapy were found.
3.3.1. Case reports
The last case report analysis on NF-induced polyneuropathy was
performed by Toole and Parrish26 in 1973. They reviewed 137 cases
of NF-induced polyneuropathy, 100 of which were followed-up
long term, and 10 of which had treatments longer than 90 days.
Of those 100 patients, 34% made a complete recovery, 45% a partial
recovery, 13% showed no improvement, and 8% died. Recovery
usually occurred within a few days to several months after NF was
discontinued. However, these data include patients both on long-
and short-term NF, and the age data were not provided.
Most case studies were reported in the 1960s to the 1980s, and
this review presents available recent reports. Tan et al27 chronicled
twowomen, aged 59 years and 53 years, whowere on long-termNF
suppression and suffered general dysesthesias and pelvic pain,
respectively. The ﬁrst woman remained symptomatic 3 years after
discontinuation of NF, and the second woman's symptoms
improved. Yiannikas et al28 reported on a 71-year-old woman on
NF therapy for almost 1 year who developed paresthesia of her
hands and feet along with decreased deep tendon reﬂexes. None of
these three patients discussed had other causes of neuropathy such
as diabetes.
4. Discussion
In this review, we carefully studied all adverse events reported
with NF so that the practicing physician can be aware of the
available literature on this topic when discussing risks of long-term
NF exposure with his/her older patients. Several observations were
made for lung toxicity including the importance of earlyPulmonary AR case studies related to chronic use of nitrofurantoin in older women.
Author Age
(y)
Length of use,
dosage
Pulmonary reaction Symptoms
Sakata et al1,
2014
69 2.5 y, 100 mg every
other d
Crackles, interstitial
inﬁltrates, ground glass
opacities, giant cell
granulomas
2 wk dyspn
Ghimire and
Nepal2, 2013
71 Not noted Not noted Dyspnea, an
Mullerpattan
et al3, 2013
67 1 y prior and 1 mo,
not noted
Interstitial pneumonia with
bilateral reticular shadows,
ground glass opacities,
bilateral crackles
Rapid onse
tachypnea
Madani and
Mann4, 2012
88 4 y, not noted Interstitial lung disease 6 mo of pro
and dyspne
ﬁbrosis on
Hardak et al5,
2010
85 1 y, not Noted Diffuse reticular inﬁltrates,
ground glass opacities
3 mo fever,
cough, crac
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Urological Science (2016), http://dx.doi.org/10.1016/j.urols.2016.07.004recognition of persistent cough and dyspnea with subsequent
discontinuation of NF. Recovery from pulmonary ARs depends on
the type of pulmonary reaction, how soon NF was discontinued
after the presentation of symptoms, and the degree of symptom
severity. As a result, this review suffers from under-reporting of all
NF-related ARs. However, even if only one out of every 100 pul-
monary ARs is reported, the rate of pulmonary ARs would still be
very low. Only a registry could keep track of these events in a
longitudinal study. Such an effort may be necessary to better
delineate the real risks of using NF in a long-term chronic fashion.
The rates of liver and nerve toxicity are even less frequent than
lung toxicity. Nonetheless, it is appropriate for the physician to
monitor their patients on long-term NF prophylaxis, and consider
“regular monitoring” with inquiries on peripheral neuropathy
symptoms and possible liver function tests.29
The combined worldwide experience with chronic NF therapy
remains modest at best in establishing the rates of ARs for older
patients. There is sufﬁcient information to call attention to ARs, but
it appears that large-scale and long-term prospective studies are
still needed. For the practicing urologist, NF remains a good treat-
ment option in the acute setting of urinary tract infection with an
adequate renal function. It is important to be acquainted with the
Beers criteria4 and exercise caution and proper monitoring29 in the
long-term use of NF for antibiotic suppression in the individualized
care of older adults.5. Conclusion
The currently reported rates of pulmonary, hepatic, and nerve
ARs related to the long-term use of NF remain very small. Although
pulmonary, nerve, or liver ARs resulting from long-term NF pro-
phylaxis in older patients treated for urinary tract infections are
potentially serious, they should not deter from the cautious use of
NF in this population.Conﬂicts of interest
The authors have nothing to disclose.Appendix 1Death Treatment Recovery
ea and fatigue No Discontinued, home
oxygen
Back to baseline at 3 y
follow-up
emic No Discontinued Yes, glucose-6-phosphate
dehydrogenase deﬁciency
t of dyspnea, Yes Discontinued, IV
methylprednisone
500 mg for 3 d,
pirfenidone and N-
acetyl-cysteine
Deteriorated for 1 mo until
respiratory failure
ductive cough
a, crepitation,
CT
No Discontinued,
prednisone
Yes
dyspnea, dry
kles
No Discontinued Resolution
of nitrofurantoin for urinary tract prophylaxis in the older patient,
(continued )
Author Age
(y)
Length of use,
dosage
Pulmonary reaction Symptoms Death Treatment Recovery
74 3 y, not noted FEV1¼ 58%, FVC¼ 68%,
diffuse reticular inﬁltrates
3 y dyspnea, dry cough,
fatigue, crackles
No Discontinued Resolution
72 6 mo, not noted Diffuse reticular inﬁltrates 6 mo, dyspnea, dry cough,
fatigue
No Discontinued Resolution
75 3 y, not noted FEV1¼ 44%, FVC¼ 37%,
diffuse reticular inﬁltrates,
peripheral ﬁbrosis, pleural
effusion
1 y, dyspnea, decreased
breath sounds
No Steroids, discontinued Fibrosis
86 2 y, not noted FEV1¼ 44%, FVC¼ 55%,
diffuse reticular inﬁltrates
6 mo, dry cough, dyspnea,
crackles
No Discontinued Resolution
75 5 y, not noted FEV1¼ 67%, FVC¼ 69%,
DLCO¼ 37%, ground glass
opacities
1 y, dyspnea, crackles No Steroids, discontinued Partial resolution
70 14 mo, not noted Ground glass opacities 2 mo, dry cough, dyspnea,
malaise, crackles
No Steroids, discontinued Resolution
Martins et al6,
2008
74 3 y, not noted Subpleural interstitial
thickening, chronic
eosinophilic pneumonia
Chronic cough, 20 mo ago
x-ray showed ﬁbrosis,
crackling rales
No Oral and inhaled
corticosteroids, later NF
discontinued
No signiﬁcant
improvement on imaging,
dyspnea and rales resolved
after 15 mo
Bhullar et al7,
2007
71 3 y, 100 mg every
other d
Patchy airspace disease,
calciﬁed hilar
lymphadenopathy,
restrictive pattern
3 y intensifying dyspnea,
cough
No Discontinued 1 wk subjective
improvement, 5 mo FVC
normal, 7 mo clear on
radiographs
Lin and Bhally8,
2007
67 5 y, 50 mg/d Reduced FEV1 and FVC,
bilateral ground glass
opacity
8 wk nonproductive cough,
2 wk progressive dyspnea,
crackles, hypoxia
No Discontinued,
prednisone 40 mg
Prolonged hospital course,
2 mo symptoms and chest
x-ray improved
Hargett, et al9,
2006
77 9 mo, not noted Cellular interstitial
inﬁltrates and scattered
MGC consistent with GIP
6 mo dyspnea No Discontinued,
prednisone
2 mo, return to normal
Bidad and
Harries-
Jones10, 2004
76 14 mo, not noted Interstitial and reticular
shadowing, FEV1/
FVC¼ 91%, like pulm
ﬁbrosis or pneumonitis
6 wk tachypnea,
tachycardic, crackles
No Discontinued,
prednisolone
2 wk, less breathlessness;
later reduced shadowing,
parenchymal abnormalities
Fawcett and
Ibrahim11,
2001
82 4 y, 50 mg/d Reduced FEV1 and FVC,
mosaic perfusion, patchy
ground glass opacities,
biopsy suggestive of BOOP
2 y productive cough,
increasing breathlessness
No Discontinued,
prednisone 30 mg/
d reduced over 6 wk
8 mo return to baseline,
FEV1 and FVC improved,
improved basal reticular
shadowing
Sheehan et al12,
2000
75 3 y, not noted Widespread reticular
pattern, ground glass
changes, parenchymal
distortion
2 y increasing dyspnea,
crackles
No Distincontinued, oral
methylprednisolone
6 wk, return to normal
Robinson13,
1983
71 10 mo, 300 mg/d Bilateral reticular
shadowing, reduced DLCO
Dyspnea, nonproductive
cough, bilateral
crepitations, sensorimotor
neuropathy
No Discontinued 2 y, no improvement in
pulmonary symptoms
Willcox et al14,
1982
65 4 y, not noted Small lung ﬁelds, bilateral
shadowing on x-ray,
restrictive disease
1 y progressive dyspnea,
dry cough, bilateral
crackles, poor chest
expansion
No Discontinued,
prednisone 40 mg/
d withdrawn gradually
over a mo
1 mo, chest x-ray clearer,
improvement in pulmonary
fxn tests, cough subsided,
crackles almost gone
Oxenhandler15,
1977
67 4 y, not noted Bilateral ﬁbrosis, vasculitis
of pulmonary veins
Unproductive cough, 1 mo
later hospitalized for
dyspnea, 7 mo later ﬁbrosis,
1 mo later fever, malaise,
dyspnea
Yes,
due to
INH
5 d prednisone, 10
d prednisone, last
hospital visit
discontinued NF, with
20 mg/d prednisone
and 300 mg/d INH
Unexplained fever 2 mo
after INH started, died
Kursh et al16,
1975
78 Intermittent few y,
not noted
Bilateral pleural effusions,
bilateral diffuse pulmonary
inﬁltrate, pulmonary
ﬁbrosis
2 mo severe dyspnea; later
fever, productive cough,
egophony and rales
Yes Hospitalized twice, was
intubated the second
time, NF discontinued 3
d prior to death
In hospital, developed
incomplete right bundle
branch block, died
68 >6 y, 50 mg/d Chronic interstitial
pneumonitis and ﬁbrosis,
bilateral diffuse process at
bases of lungs, restrictive
disease
> 4 y of cough, dyspnea No Dexamethasone
0.75mg 2/d, later NF
discontinued
6 wk, less dyspnea, patient
improved, pulmonary
symptoms present 6 y later
Rosenow
et al17, 1968
75 Intermittent for
approx. 7 y, 50 mg
4/d for 2e3 wk,
5/y
Restrictive ventilation,
impaired CO diffusion,
chronic interstitial
pneumonitis, focal
interstitial ﬁbrosis
7 wk, cough, dyspnea.
Cyanosis, bilateral
decreased chest expansion
crackling, rales, T wave
changes
No Discontinued, 0.25 mg/
d digitoxin, 5mg 4/
d prednisone
5 wk, symptomatic
improvement, CO diffusion
still impaired
66 15 mo, not noted Diffuse bilateral interstitial
process, restrictive
pulmonary fxn and
impaired CO diffusion
5 mo progressive
nonproductive cough,
dyspnea, chest pain,
bilateral crackling rales
No Discontinued, 10 mg
4/d prednisone, 7 mo
smaller dose of
prednisone
4 wk, clearing of diffuse
process, 8 mo, no imaging
abnormality, CO diffusion
increased
BOOP¼ bronchiolitis obliterans organizing pneumonia; CO¼ carbon monoxide; CT¼ computed tomography; DLCO¼ diffusing capacity for carbon monoxide; FEV1¼ forced
expiratory volume of 1 second; FVC¼ forced vital capacity; fxn¼ function; GIP¼ giant cell interstitial pneumonia; INH¼ isoniazid; IV¼ intravenous, MGC¼multinucleated
giant cells; NF¼ nitrofurantoin; PFT¼ pulmonary function tests; TLC¼ total lung capacity.
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